Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multivalent influenza and RSV/hMPV/PIV3 vaccines in healthy adults
NCT06850051Phase 1Completed
- Sponsor
- Sanofi
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of trivalent inactivated influenza vaccine high-dose and RSV/hMPV/PIV3 formulation 1 in influenza, respiratory syncytial virus infection (RSV), human metapneumovirus infection (HMPV) and 1 more (9 arms), sponsored by Sanofi. Primary endpoints: Presence of any unsolicited systemic Adverse Events reported within 30 minutes after vaccination, Presence of solicited injection site and systemic reactions occurring through 7 days after vaccination and 5 more. Started Mar 2025; status: completed.
02
Drugs
trivalent inactivated influenza vaccine high-doseRSV/hMPV/PIV3 formulation 1
03
Conditions
influenzarespiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)Parainfluenza virus type 3 infection (HPIV-3)
Beyond the preview
Go deeper on NCT06850051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06850051.